Viking Therapeutics has completed patient enrollment for its Phase 3 VANQUISH-2 trial testing subcutaneous VK2735, a dual GLP-1 and GIP receptor agonist, in adults with obesity and type 2 diabetes. The trial involves about 1,000 participants and will assess body weight changes over 78 weeks, with results expected in 2027. This follows the completion of VANQUISH-1 and positive Phase 2 results showing significant weight loss and good safety. VK2735 aims to offer a new treatment option for metabolic disorders, with both subcutaneous and oral formulations under development.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
